In recent years, the two most promising approaches to limiting the damage of the oxidative heart caused by diabetes are to inhibit NADPH oxidation by pharmaceutical activation of NRF2 [126, 198, 199] and combined NOX1/NOX4 inhibitor GKT137831, as demonstrated in several preclinical models of diabetes [200–202]. Here, NOX1 is linked to diabetes mellitus.